MHRA
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...MHRAFeb 5th 2024
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...MHRAFeb 5th 2024
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...MHRAFeb 5th 2024
Guidance: Advice for consumersMHRAFeb 2nd 2024
Class 4 Medicines Defect Information: Exeltis UK Limited, Gepretix 100mg Capsules, EL (24)A/04MHRAFeb 1st 2024
Press release: MHRA announces two new UK Approved Bodies to certify medical devicesMHRAJan 31st 2024
Press release: Omjjara licensed for anaemic myelofibrosis patients to treat the symptoms of their diseaseMHRAJan 31st 2024
Guidance: Medical devices: UK approved bodiesMHRAJan 30th 2024